Related Experiment Videos
Summary
Serum lactic dehydrogenase (LDH) levels are higher in patients with pheochromocytoma, a neuroendocrine tumor. LDH type 3 is prominent in both serum and tumor tissue, suggesting the tumor as the source.
Area of Science:
- Biochemistry
- Oncology
- Endocrinology
Background:
- Lactic dehydrogenase (LDH) is a cytosolic enzyme present in neural and endocrine tissues.
- Pheochromocytoma is a neuroendocrine neoplasm originating from chromaffin cells.
Purpose of the Study:
- To investigate serum and tumor tissue LDH levels in patients with pheochromocytoma.
- To determine if LDH activity can serve as a biomarker for pheochromocytoma.
Main Methods:
- Measurement of serum total LDH activity and isoenzyme profiles in 15 pheochromocytoma patients.
- Comparison of LDH levels with essential hypertension, normotensive controls, and other secondary hypertension groups.
- Analysis of LDH content in pheochromocytoma and normal adrenal tissues.
Main Results:
- Mean serum total LDH activity was significantly higher in pheochromocytoma patients compared to control groups.
- LDH type 3 was the predominant isoenzyme in both serum and tumor tissue.
- Pheochromocytoma tissue exhibited markedly higher LDH levels than normal adrenal glands.
Conclusions:
- Elevated serum LDH, particularly type 3, suggests pheochromocytoma as the source in affected patients.
- Despite a high true-positive rate (100%), a 40% false-negative rate limits serum LDH's utility as a sole screening test.
- Further investigation for pheochromocytoma is not yet recommended based solely on elevated serum LDH in hypertensive individuals.